Dynamics of Acquired Resistance to Nivolumab Therapies Varies From Administration Strategies

• Published in: Clinical therapeutics Vol. 43; no. 12; pp. 2088 - 2103
• Main Authors: Ji, Jiatong, Wu, Hong, Feng, Xiaobing, Liu, Xiaoquan, Huang, Chenrong, Zheng, Shuyun, Zou, Jianjun, Liao, Jun
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2021; Elsevier Limited
• Subjects: Antigens; Birth rate; Cancer research; Cancer therapies; Clinical trials; Cloning; Competition; Computer applications; Computer Simulation; dosing schedule; Drug Administration Schedule; Drug dosages; drug resistance; drug sensitivity; Evolution; Game theory; Genotype & phenotype; Humans; Immunotherapy; Internal Medicine; Janus kinase; Kinases; Lung cancer; Lymphocytes; Monoclonal antibodies; Mutation; Neoplasms - drug therapy; nivolumab; Nivolumab - therapeutic use; Pharmacokinetics; Targeted cancer therapy; Treatment Outcome; tumor; Tumors; drug sensitivity; dosing schedule; drug resistance; nivolumab; tumor

•We developed innovative model combining evolutionary dynamics and pharmacokinetics.•We adopted modeling method to simulate resistance which is difficult to achieve in vivo experiments.•The results indicate increasing the dose or shortening the doses interval can promote drug resistance.•The paramet...